白雲山(600332.SH):廣州醫藥發行H股獲中證監核准
格隆匯7月5日丨白雲山(600332.SH)公佈,廣州醫藥於2021年7月2日收到中國證監會出具的《關於核准廣州醫藥股份有限公司發行境外上市外資股的批覆》(證監許可[2021]2187號),批覆內容如下:
一、核准廣州醫藥發行不超過938,900,442股境外上市外資股,每股面值人民幣1元,全部為普通股。完成此次發行後,廣州醫藥可到香港聯交所主板上市。
二、上市後15個工作日內,廣州醫藥應將非境外上市股份集中登記存管在中國證券登記結算有限責任公司,並將股份集中登記存管及本次發行上市的情況書面報吿中國證監會。
三、本批覆自核準之日起12個月內有效。
四、廣州醫藥在境外發行股票和上市過程中,應嚴格遵守境內外有關法律、法規和規則。
廣州醫藥此次發行上市尚需取得香港聯交所上市委員會批准以及公司與廣州醫藥的最終決定,並受限於市場情況及其他因素,該事項仍存在不確定性。因此,公司股東及潛在投資者務請注意,公司概不保證廣州醫藥此次境外發行上市是否會進行,亦不能保證將於何時進行。公司將根據該事項的進展情況及時履行信息披露義務,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.